Verastem, Inc. current report, 12 October 2018

Verastem, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Verastem, Inc. on October 18, 2018, covering events occurring between October 12, 2018, and October 17, 2018. The filing addresses significant changes to the Company's management team and Board of Directors.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.

Material Changes

  • Resignation of Chief Medical Officer: NgocDiep Le, MD, PhD, resigned as Chief Medical Officer on October 12, 2018, to pursue other professional opportunities.
  • Resignation of Director: S. Louise Phanstiel resigned from the Board of Directors and its audit committee on October 16, 2018.
  • Election of New Director: On October 17, 2018, the Board unanimously elected Gina Consylman as a Class III director and Chairperson of the audit committee, effective immediately.
  • Compensatory Arrangements: In connection with her appointment, Ms. Consylman received a stock option grant for 50,000 shares of common stock. She is also eligible for annual cash retainer fees and future stock option grants under the director compensation policy, and entered into a customary indemnification agreement.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, or specific risk factors. The document serves solely to disclose the personnel changes listed above.

Key Facts for Investor Verification

  • Verify the status of the Chief Medical Officer role following Dr. Le's resignation.
  • Confirm the composition of the Board of Directors and the Audit Committee following the election of Gina Consylman.
  • Review the terms of the 50,000 share stock option grant issued to Ms. Consylman.
  • Check for any subsequent press releases (Exhibit 99.1) regarding the transition of medical leadership.